title: Adaptive trial of personalized radiotherapy for intrahepatic cancer.
abstract: Primary liver cancer is a major health problem worldwide, with more than 500,000 new cases diagnosed yearly. Preliminary results suggest excellent local control rates of intrahepatic malignancies treated with stereotactic body radiation therapy (SBRT), but some patients have experienced life-threatening toxicity because the current approaches cannot accurately estimate residual liver function after treatment. An early-phase trial of SBRT in hepatocellular carcinoma patients, including those with compromised liver function, is described. Patients are treated with three fractions of SBRT, then treatment is paused for 4 weeks and liver function is evaluated by means of an indocyanine green assay. The size of the final two fractions of SBRT is determined based on the patient's indocyanine green assay after the first three fractions, so that the therapy is personalized to each patient's sensitivity to radiation. The sensitivity to the liver of the final two fractions of SBRT, compared with the first three fractions, is re-estimated using a Bayesian model throughout the trial, so this is an adaptive trial. The operating characteristics of the trial are described by Monte Carlo simulations.
authors.affiliation: Biostatistics Facility, University of Pittsburgh Cancer Institute, Suite 325 Sterling Plaza, 201 N Craig St, Pittsburgh, PA 15213, USA, Tel.: +1 412 383 1591, ,  dpn7@pitt.edu.
authors.forename: Daniel
authors.initials: D
authors.lastname: Normolle
authors.forename: Charlie
authors.initials: C
authors.lastname: Pan
authors.forename: Edgar
authors.initials: E
authors.lastname: Ben-Josef
authors.forename: Theodore
authors.initials: T
authors.lastname: Lawrence
references.citation: Am J Surg. 1992 May;163(5):515-8
references.pmid: 1575310
references.citation: J Clin Oncol. 2004 Jan 15;22(2):238-43
references.pmid: 14665608
references.citation: Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22
references.pmid: 2032882
references.citation: Arch Surg. 1984 Mar;119(3):264-8
references.pmid: 6696619
references.citation: J Clin Oncol. 2007 Oct 10;25(29):4587-92
references.pmid: 17925553
references.citation: Int J Radiat Oncol Biol Phys. 1992;23(4):781-8
references.pmid: 1618671
references.citation: Gynecol Oncol. 1986 Jul;24(3):373-80
references.pmid: 3721310
references.citation: Ann Intern Med. 2003 Nov 18;139(10):817-23
references.pmid: 14623619
references.citation: J Clin Oncol. 2008 Feb 1;26(4):657-64
references.pmid: 18172187
references.citation: Acta Oncol. 2006;45(7):848-55
references.pmid: 16982549
references.citation: Int J Cancer. 2001 Oct 15;94(2):153-6
references.pmid: 11668491
references.citation: Surg Gynecol Obstet. 1979 Dec;149(6):852-4
references.pmid: 388703
references.citation: Transplantation. 1991 Apr;51(4):801-6
references.pmid: 2014533
references.citation: Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):810-21
references.pmid: 12095546
references.citation: Lancet. 1998 Jan 17;351(9097):214-5
references.pmid: 9449893
references.citation: J Hepatobiliary Pancreat Surg. 2005;12(1):16-22
references.pmid: 15754094
references.citation: J Clin Oncol. 2001 Jan 1;19(1):164-70
references.pmid: 11134209
references.citation: Acta Oncol. 2006;45(7):856-64
references.pmid: 16982550
references.citation: Stat Med. 1995 Feb 28;14(4):357-79
references.pmid: 7746977
references.citation: CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
references.pmid: 18287387
references.citation: Int J Radiat Oncol Biol Phys. 1993 Sep 1;27(1):117-23
references.pmid: 8365932
references.citation: Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1237-48
references.pmid: 7713785